JP7696353B2 - オメカムチブメカルビル製剤 - Google Patents

オメカムチブメカルビル製剤 Download PDF

Info

Publication number
JP7696353B2
JP7696353B2 JP2022548433A JP2022548433A JP7696353B2 JP 7696353 B2 JP7696353 B2 JP 7696353B2 JP 2022548433 A JP2022548433 A JP 2022548433A JP 2022548433 A JP2022548433 A JP 2022548433A JP 7696353 B2 JP7696353 B2 JP 7696353B2
Authority
JP
Japan
Prior art keywords
tablet
omecamtiv mecarbil
coating film
pharma
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022548433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513249A5 (enExample
JP2023513249A (ja
Inventor
ミンダ ビー，
ユアン－ホン キアン，
ハオ ロウ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JP2023513249A publication Critical patent/JP2023513249A/ja
Publication of JP2023513249A5 publication Critical patent/JP2023513249A5/ja
Application granted granted Critical
Publication of JP7696353B2 publication Critical patent/JP7696353B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
JP2022548433A 2020-02-10 2021-02-10 オメカムチブメカルビル製剤 Active JP7696353B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062972506P 2020-02-10 2020-02-10
US62/972,506 2020-02-10
PCT/US2021/017429 WO2021163172A1 (en) 2020-02-10 2021-02-10 Omecamtiv mecarbil tablet

Publications (3)

Publication Number Publication Date
JP2023513249A JP2023513249A (ja) 2023-03-30
JP2023513249A5 JP2023513249A5 (enExample) 2024-02-08
JP7696353B2 true JP7696353B2 (ja) 2025-06-20

Family

ID=74858801

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548433A Active JP7696353B2 (ja) 2020-02-10 2021-02-10 オメカムチブメカルビル製剤

Country Status (9)

Country Link
US (1) US20230090391A1 (enExample)
EP (1) EP4103159A1 (enExample)
JP (1) JP7696353B2 (enExample)
CN (1) CN115279349A (enExample)
AU (1) AU2021221106A1 (enExample)
BR (1) BR112022015457A2 (enExample)
CA (1) CA3168513A1 (enExample)
IL (1) IL295490A (enExample)
WO (1) WO2021163172A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
EP3821882A1 (en) 2013-03-14 2021-05-19 Amgen Inc. Heterocyclic compounds and their uses
MX2021009594A (es) 2017-06-30 2022-10-24 Amgen Inc Sintesis de omecamtiv mecarbil.
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
DK3594199T3 (da) 2018-07-09 2020-09-14 Fis Fabbrica Italiana Sintetici Spa Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf
EP3837009A1 (en) 2018-08-17 2021-06-23 Amgen, Inc Salts and crystal forms of omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
IL302850A (en) 2020-11-12 2023-07-01 Amgen Inc Methods of treating heart failure by administering OMECAMTIV MECARBIL
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2023164452A2 (en) * 2022-02-22 2023-08-31 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513683A (ja) 2013-03-14 2016-05-16 アムジエン・インコーポレーテツド 複素環化合物およびその使用
JP2016513678A (ja) 2013-03-14 2016-05-16 アムジエン・インコーポレーテツド 複素環式化合物及びそれらの使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808321A (en) * 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
JP2020526483A (ja) * 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513683A (ja) 2013-03-14 2016-05-16 アムジエン・インコーポレーテツド 複素環化合物およびその使用
JP2016513678A (ja) 2013-03-14 2016-05-16 アムジエン・インコーポレーテツド 複素環式化合物及びそれらの使用

Also Published As

Publication number Publication date
CA3168513A1 (en) 2021-08-19
WO2021163172A1 (en) 2021-08-19
BR112022015457A2 (pt) 2022-10-04
US20230090391A1 (en) 2023-03-23
JP2023513249A (ja) 2023-03-30
CN115279349A (zh) 2022-11-01
EP4103159A1 (en) 2022-12-21
IL295490A (en) 2022-10-01
AU2021221106A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
JP2023513249A (ja) オメカムチブメカルビル製剤
RU2207856C2 (ru) Способ лечения сердечно-сосудистых заболеваний
KR101792299B1 (ko) 항응고제의 용출 개선 방법
US20190125711A1 (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
TWI483748B (zh) 含有氫嗎啡酮（ｈｙｄｒｏｍｏｒｐｈｏｎｅ）和納洛酮（ｎａｌｏｘｏｎｅ）之藥學組成物
JPH11505542A (ja) 毎日一回投与するための、非晶質活性成分の一定のかつ制御された放出を行う三相型医薬製剤
CN103550190A (zh) 含有碱性药物或其盐的基质型缓释制剂
US9387178B2 (en) Modified release tranexamic acid formulation
JP2012516299A (ja) 有機化合物のガレヌス製剤
US9387166B2 (en) Controlled release oral dosage form comprising oxycodone
EP2533766B1 (en) Pharmaceutical mini-tablets for sustained release of flecainide acetate
JP2022544167A (ja) ニトロキソリンを含む医薬組成物、ニトロキソリン経口固形錠剤、その調製方法、及びその使用
JP2010536798A (ja) 難溶性薬物の生体利用率を制御するための方法及び組成物
EP3796908B1 (en) Controlled release propiverine formulations
EP4251154A1 (en) Sustained release formulation compositions comprising propiverine
US20080182908A1 (en) Pharmaceutical compositions comprising memantine
JP2025512011A (ja) デフェリプロンを含む修飾放出医薬製剤
JP6719299B2 (ja) ゲフィチニブを有効成分とする医薬組成物
WO2021116244A1 (en) Modulation of drug release and bioavailability of compositions containing dolutegravir sodium and other anti hiv drugs
WO2010099150A1 (en) Pharmaceutical tablet and process
EP2543361A1 (en) Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts
EP2543362A1 (en) Sustained release pharmaceutical oral solid dosage form of dronedarone or one of its pharmaceutically acceptable salts
EP2543363A1 (en) Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts
NZ718686B2 (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
HK1180252B (en) Method for improving dissolvability of anticoagulant

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250430

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250605

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250610

R150 Certificate of patent or registration of utility model

Ref document number: 7696353

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150